Table 3 List of clinical trials included for PFS analysis
From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
| Study | No. patients | Median PFS (months) | HR |
|---|---|---|---|
| CA209-067 |
n + i = 314 n = 316 |
n + i = 11.5 n = 6.93 | HR 0.79 |
| CA209-227 (PFS TMB High) |
n + i = 101 n = 102 |
1 yr n + i = 42% n = 29% | HR 0.75 |
| CA209-227 (PFS PD-L1 > 1%) |
n + i = 396 n = 396 |
n + i = 5.1 n = 4.2 | HR 0.83 |